Concourse Financial Group Securities, Inc. Kaleido Biosciences, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change
Q2 2022 Aug 09, 2022	SELL	$0.05 - $1.7 $0 - $0	0 Closed
Q1 2022 May 09, 2022	BUY	$1.3 - $2.7 $0 - $0	0 New
Q4 2021 Feb 07, 2022	BUY	$2.39 - $6.02 $0 - $0	0 New
Q3 2021 Nov 09, 2021	BUY	$5.36 - $7.99 $0 - $0	0 New
Q2 2021 Aug 13, 2021	BUY	$5.82 - $8.72 $0 - $0	0 New
Q1 2021 May 13, 2021	BUY	$7.2 - $16.82 $0 - $0	0 New
Q4 2020 Feb 02, 2021	BUY	$5.77 - $11.33 $0 - $0	0 New
Q3 2020 Nov 13, 2020	BUY	$5.09 - $11.07 $0 - $0	0 New
Q2 2020 Aug 13, 2020	BUY	$4.62 - $8.01 $0 - $0	0 New
Q1 2020 May 13, 2020	BUY	$3.62 - $9.49 $0 - $0	0 New
Q4 2019 Feb 14, 2020	BUY	$5.02 - $8.87 $0 - $0	0 New
Q3 2019 Nov 13, 2019	BUY	$6.74 - $11.3 $0 - $0	0 New
Q2 2019 Aug 13, 2019	BUY	$11.25 - $18.1 $0 - $0	0 New
Q1 2019 May 15, 2019	BUY	$12.71 - $15.0 $0 - $0	0 New

Others Institutions Holding KLDO

# of Institutions

Shares Held

2.65K

Call Options Held

Put Options Held

View Full List

About Kaleido Biosciences, Inc.

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

More about KLDO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account